Phase II study of thalidomide in patients with metastatic malignant melanoma

Melanoma Research

Volumn 14, Issue 6, 2004, Pages 527-531

  Reiriz, André B ^a,d   Richter, Marc F ^a,b   Fernandes, Sabrina ^a   Cancela, Anna I ^a   Costa, Teresa D ^c   Di Leone, Luciane P ^a   Schwartsmann, Gilberto ^a,c  

^a S Amer Off Anticancer Drug Devmt   (Brazil)

^b UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d NONE   (Brazil)

Author keywords

Clinical trial; Malignant melanoma; Thalidomide

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; TEMOZOLOMIDE; THALIDOMIDE; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG TOLERABILITY; DRY SKIN; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOMODULATION; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MEAN RESIDENCE TIME; MELANOMA; METASTASIS; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RASH; RETROPERITONEAL CANCER; SOFT TISSUE METASTASIS; SOMNOLENCE; TREMOR; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; AGED; ANGIOGENESIS INHIBITORS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; SKIN NEOPLASMS; SURVIVAL RATE; THALIDOMIDE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 13544275854     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200412000-00014     Document Type: Article

References (20)

1. Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, et al. A New American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000; 88:1484-1491.
2. Atkins MB. Management of Stage IV Melanoma. Educational Book. Thirty-Eighth Annual Meeting of the American Society of Clinical Oncology (ASCO), May 18-21, 2002, Orlando, FL, USA. Orlando, FL: ASCO; 2002, pp. 175-183.
3. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
4. Folkman J. What is the role of angiogenesis in metastasis from cutaneous melanoma? Eur J Clin Oncol 1987; 23:361-363.
5. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991; 324:1-8.
6. Weidner N, Carrol PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143:401-409.
7. Maeda K, Chung YS, Takatsuka S, Ogawa Y, Onoda N, Sawada T, et al. Tumor angiogenesis and tumor cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer 1995; 72:319-323.
8. Srivastava A, Laidler P, Davies RP, Morgan K, Hughes LE. The prognostic significance of tumor vascularity in intermediate-thickness skin melanoma. A quantitative histologic study. Am J Pathol 1988; 133: 419-423.
9. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91:4082-4085.
10. Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: a review of its mechanism of action, side effects and potential uses. J Am Acad Dermatol 1996; 35:969-979.
11. Eleutherakis-Papoiakovou V, Bamias A, Dimopoulos MA. Thalidomide in cancer medicine. Ann Oncol 2004; 15:1151-1160.
12. Hwu WJ, Krown SE, Menell JH, Panageas KS, Merrel J, Lamb LA, et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003; 21:3351-3356.
13. Danson S, Lorigan P, Arance A, Clamp A, Ranson M, Hodgetts J, et al. Randomized phase II study of temozolomide given every 8 h or daily with either interferon alpha-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol 2003; 21:2551-2557.
14. Pawlak WZ, Legha SS. Phase II study of thalidomide in patients with metastatic melanoma. Melanoma Res 2004; 14(1):57-62.
15. Eriksson T, Björkman S, Fyge A, Ekberg H. Determination of thalidomide in plasma and blood by high-performance liquid chromatography: avoiding hydrolytic degradation. J Chromatogr Part B 1992; 582:211-216.
16. Simon R. Optimal two-stage design for phase II clinical trials. Controlled Clinical Trials 1989; 10:1-10.
17. Piscitelli SC, Figg WD, Hahn B, Kelly G, Thomas S, Walker RE. Single dose pharmacokinetics of thalidomide in HIV infected patients. Antimicrob Agents Chemother 1997; 41:2797-2799.
18. Figg WD, Raje S, Bauer KS, Tompkins A, Venzon D, Bergan R, et al. Pharmacokinetics of thalidomide in an elderly prostate cancer population. J Pharm Sci 1999; 88:121-125.
19. Baidas SM, Winer EP, Fleming GF, Harris L, Pluda JM, Crawford JG, et al. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 2000; 14:2710-2717.
20. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18:708-715.